The condition at the heart of the research is fracture-related infection, or FRI, one of the most feared complications of operative fracture care. Reported infection rates range from roughly 1 to 2 percent in closed fractures to as high as 29 percent in open fractures, where the bone breaks through the skin and bacteria have a direct route to the implant. Diagnosing FRI is notoriously difficult because symptoms vary widely, and conventional culture methods frequently come back negative or inconclusive. Literature reviewed by the team indicates that between 9 and 22 percent of confirmed fracture-related infections yield no bacterial growth at all on standard cultures, leaving surgeons to treat blindly.

Sonication offers a way around one of the central problems: biofilm. Bacteria on implanted metal do not float freely; they encase themselves in a sticky, protective matrix that clings tenaciously to the implant surface. Tissue samples taken around the hardware may capture only scattered organisms, while the bulk of the microbial population remains locked on the metal itself. Sonication uses high-frequency sound waves, typically delivered in a specialized bath, to generate powerful microscopic forces that dislodge bacteria from the biofilm into a surrounding fluid. That fluid can then be cultured, theoretically revealing the true microbial picture. The approach has already proven its worth in periprosthetic joint infection, where multiple studies have shown higher sensitivity than tissue cultures alone.

In the new study, published in the Journal of Bone and Joint Infection, Anas Zouitni and colleagues analyzed prospectively collected data from patients who underwent partial or complete removal of osteosynthesis implants between July 2012 and May 2021 at their tertiary university hospital. The team aimed to send every removed implant for sonication, regardless of whether infection was suspected. To be included in the analysis, patients needed at least three tissue cultures taken during surgery, each collected with separate sterile instruments and incubated for a full fourteen days on multiple media types, including blood, chocolate, McConkey, and Brucella agars under both aerobic and anaerobic conditions.

The sonication protocol itself was precise. Retrieved hardware was transported to the microbiology laboratory in sterile hard-polypropylene containers and processed within six hours of removal. A sodium chloride solution was added to cover at least 90 percent of the implant, and the container was placed in a sonication bath for one minute at 40 kilohertz, with manual vortexing for 30 seconds before and after. Aliquots of the resulting fluid were plated onto agar media and inoculated into aerobic and anaerobic blood culture bottles, all incubated for fourteen days. Bacterial identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, a rapid technique that fingerprints proteins to identify organisms at the species level.

The researchers classified 96 patients using the international consensus criteria for fracture-related infection established by the AO Foundation and the European Bone and Joint Infection Society. Before sonication results were considered, the cohort contained 14 aseptic cases, 35 suggestive FRI cases, and 47 confirmed FRI cases. After incorporating sonication fluid culture results, four cases moved from aseptic to suggestive FRI, and three cases escalated from suggestive to confirmed FRI. In three additional cases where infection had been confirmed on non-microbiological grounds, sonication was needed together with a single positive tissue culture to achieve full microbiological confirmation. In total, the technique was essential for confirming the diagnosis in about 6 percent of confirmed infections.

The diagnostic performance numbers tell a nuanced story. Tissue cultures alone achieved a sensitivity of 74 percent and a specificity of 98 percent. Sonication fluid cultures on their own were more sensitive, at 84 percent, but less specific, at 83 percent. The real power emerged when the two methods were combined: sensitivity rose significantly from 74 to 88 percent, a difference the authors report as statistically significant. Specificity, however, dropped from 98 to 83 percent with the combination, reflecting the fact that sonication fluid, which requires extra handling steps, is more vulnerable to contamination. The team noted that 33 percent of patients classified as aseptic showed a positive sonication culture, almost all involving low-virulence organisms such as coagulase-negative staphylococci and Cutibacterium acnes, with very low bacterial counts suggesting contamination rather than true infection.

Perhaps the most clinically consequential findings concerned antibiotic therapy. Among 50 confirmed fracture-related infections, sonication results were concordant with tissue cultures in 21 cases, meaning the technique would not have changed management. But in 13 cases, sonication detected an additional virulent pathogen, all Enterococcus species, that tissue cultures had missed, directly influencing the antibiotic regimen. In another set of cases, sonication revealed additional low-virulence pathogens that could have influenced therapy in 8 cases, or 16 percent of the confirmed infections. Taken together, the authors conclude that without sonication, roughly 6 to 16 percent of confirmed FRI cases would have received suboptimal treatment because not all causative pathogens would have been identified.

The study also uncovered factors that predict when sonication will pay off. In patients who had received antibiotics in the one to fourteen days before hardware removal, sonication was positive in 10 of 12 cases while tissue cultures were positive in only 8, reinforcing the idea that sonication retains value when prior antibiotics suppress growth in tissue samples. In regression analysis, implant loosening was associated with nearly fourfold higher odds of a positive sonication result, while non-union was independently associated with lower odds. Most positive sonication cultures occurred in late infections, more than ten weeks after the index surgery, when mature biofilms have had time to establish on the implant surface.

The authors argue that their findings, the first to assess the added diagnostic value of sonication in FRI using prospectively collected data, support routine use of the technique alongside standard tissue cultures, provided that an adequate number of cultures is obtained according to protocol. They note that even when the currently recommended minimum of five tissue cultures is met, as it was in about 36 percent of confirmed cases here, sonication still increased the microbiological yield. They also suggest a practical idea for future study: during debridement and implant retention procedures, exchanging a single screw for sonication culture might enhance pathogen identification without significantly extending surgery. The team recommends validation of these results and consideration of formally incorporating sonication fluid culture into future FRI consensus guidelines, a step that could help surgeons worldwide identify the microbes hiding on the metal and target them with precision.

Subject of Research: Diagnostic value of sonication fluid culture for identifying pathogens in fracture-related infection

Article Title: Sonication fluid cultures enhance pathogen identification in fracture-related-infection (FRI)

Article References: Zouitni, A., Yusuf, E., van Oldenrijk, J., Hagenaars, T., Croughs, P. D., Bos, P. K., Eygendaal, D., & Veltman, E. S. (2026). Sonication fluid cultures enhance pathogen identification in fracture-related-infection (FRI). Journal of Bone and Joint Infection, 11(4), 431-440. https://doi.org/10.5194/jbji-11-431-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-431-2026

Keywords: fracture-related infection, sonication fluid culture, biofilm, osteosynthesis implants, tissue cultures, diagnostic sensitivity, antibiotic therapy, orthopedic surgery, microbiology, MALDI-ToF, implant removal, Erasmus Medical Center

The research, led by Belal Abdo and Markus Rupp of the Department of Trauma, Hand and Reconstructive Surgery together with microbiologists at Justus Liebig University Giessen, was published in the Journal of Bone and Joint Infection. The team conducted a retrospective single-center study covering the years 2016 to 2023, screening 287 cases in which explanted osteosynthesis material had been analyzed by sonication. After applying strict inclusion criteria, 157 patients remained in the final analysis. Every included patient had undergone implant removal because of confirmed or suspected fracture-related infection, and every case had results from both peri-implant tissue culture and sonication fluid culture, allowing a direct, paired comparison of the two techniques in the same patients.

The technical logic behind the comparison is straightforward. Peri-implant tissue culture, the current standard, relies on surgeons taking small samples of tissue from immediately around the hardware during revision surgery. These samples are processed in the microbiology laboratory and incubated to see what grows. The weakness of this approach is that biofilm bacteria concentrate on the implant surface itself, not necessarily in the surrounding tissue, and prior antibiotic treatment can suppress growth in culture. False-negative microbiological results occur in up to 35 percent of cases despite clinically manifest infection, according to previous research cited by the authors. Sonication takes a different route: the removed implant is placed in a sterile container filled with 0.85 percent sodium chloride solution and exposed to ultrasound for one minute at 80 percent intensity. The sound waves dislodge biofilm organisms from the metal surface into the fluid, which is then centrifuged, concentrated, and inoculated into a panel of liquid and solid culture media, including aerobic, anaerobic, and fungal media, all incubated for up to 14 days.

The head-to-head results were strikingly balanced. Peri-implant tissue culture detected pathogens in 60.5 percent of the 157 cases, while sonication fluid culture achieved 57.3 percent. Statistically, the difference between the two methods was not significant, a finding confirmed by McNemar’s test for paired binary outcomes. Yet the overlap between the methods was far from complete. Sonication identified additional pathogens that tissue culture had missed in 17.8 percent of cases, while tissue culture uniquely detected organisms in 22.9 percent of cases. When the results of both methods were combined, the overall pathogen detection rate climbed to 70.1 percent. In other words, roughly one in ten additional infections were unmasked simply by running both tests rather than relying on either one alone.

The pathogen spectrum revealed by the two methods overlapped substantially, with methicillin-sensitive Staphylococcus aureus and coagulase-negative staphylococci predominating in both. Most positive cultures were monomicrobial, though polymicrobial growth was observed in 14.4 percent of sonication-positive cases and 21.1 percent of tissue-culture-positive cases, a numerical difference that did not reach statistical significance. Resistant organisms were rare but clinically important: methicillin-resistant Staphylococcus aureus appeared in four cases with each method, and one multidrug-resistant Enterobacterales strain was detected by each approach. The predominance of plate osteosynthesis systems, which accounted for 61.1 percent of removed implants, and screws at 18.5 percent, reflected the typical hardware profile of a trauma center population. The mean patient age was 57.4 years, and late infections occurring more than ten weeks after surgery were the most common presentation at 42.7 percent of cases.

One of the most clinically pressing questions the study addressed was whether prior antibiotic therapy undermines either diagnostic method. At the time of implant removal, 51 of the 157 patients were on ongoing antibiotic treatment or had received antibiotics within the previous 14 days, excluding routine perioperative prophylaxis. The concern is well founded: antibiotics circulating in tissue can suppress bacterial growth in culture, potentially producing misleading negative results. In this cohort, however, ongoing antibiotic therapy was not associated with a statistically significant difference in pathogen detection between the two methods. Tissue culture did show a numerically higher diagnostic yield than sonication among patients receiving antibiotics, but the authors caution that this observation should be interpreted carefully given the limited subgroup size. The finding contrasts with some earlier studies, including work by Dudareva and colleagues, who reported that both methods lost sensitivity after antibiotic exposure, and with the landmark 2007 study by Trampuz and colleagues, which found sonication particularly valuable after prior antibiotics in prosthetic joint infection.

The therapeutic consequences of the microbiological findings may be the most consequential part of the analysis. Antibiotic therapy was actually modified after revision surgery in 47.8 percent of cases. Most of these modifications, 38.9 percent of the entire cohort, were based on concordant findings from both diagnostic methods working together. Only 4.5 percent of patients had their treatment changed exclusively because of sonication results, and an identical 4.5 percent solely because of conventional culture findings. When the researchers asked a slightly different question, namely in how many cases a therapy modification would have been possible on microbiological grounds, the combined findings supported potential adjustment in 93 cases, with 8.3 percent attributable exclusively to sonication and 7.6 percent exclusively to tissue culture. The pattern is clear: the clinical value of each method lies less in replacing the other than in adding pieces to a diagnostic puzzle that neither can complete alone.

These results place fracture-related infection diagnostics in useful context. Sonication has long been an established component of the diagnostic algorithm for periprosthetic joint infection, where multiple studies have shown higher sensitivity than conventional tissue cultures, with reported sonication sensitivities ranging from roughly 52 to 100 percent depending on population and technique. For fracture-related infection, however, the evidence has been more contested. A 2018 systematic review by Onsea and colleagues concluded that sonication fluid culture may serve as a useful adjunct to tissue culture without strong evidence of superiority, and subsequent studies have split on which method performs better. The Giessen data align with the complementary view. Trenkwalder and colleagues similarly reported in 2023 that in septic and aseptic nonunion, sonication fluid culture showed lower sensitivity than tissue culture but higher sensitivity than histopathology, supporting a multimodal approach.

The study is honest about its limitations, and they matter for interpretation. Nearly half of the potentially eligible cases, 130 of 287, were excluded, mostly because they did not meet FRI criteria or because documentation was incomplete during a transition to a new hospital data system, so selection bias cannot be excluded. The retrospective design meant the exact number of intraoperative tissue samples could not always be verified, and because microbiological culture is itself part of the FRI Consensus Definition used as the reference standard, some incorporation bias is unavoidable. The single-center design also limits generalizability. Even so, the central conclusion stands on firm ground: nearly 30 percent of clinically confirmed infections remained culture negative even with both methods combined, underscoring that microbiology must be interpreted within the broader FRI diagnostic framework, which integrates clinical signs, intraoperative findings, histopathology, and culture results.

For surgeons and infectious disease specialists, the practical message is refreshingly concrete. When hardware comes out because of suspected infection, send the implant for sonication and take peri-implant tissue samples, and treat the two results as complementary rather than competing. The combined approach improved pathogen detection irrespective of prior antibiotic exposure, supported targeted antimicrobial management in nearly half of patients, and cost relatively little beyond standard laboratory processing. In an era when biofilm-embedded bacteria routinely defeat single diagnostic tests, the humble strategy of shaking the metal and swabbing the tissue, then reading both answers together, may be the most reliable tool clinicians have for turning invisible infections into treatable ones.

Subject of Research: Diagnostic comparison of implant sonication and peri-implant tissue culture for detecting fracture-related infection

Article Title: Sonication versus peri-implant tissue culture in fracture-related infection: diagnostic performance and therapeutic consequences in a single-center cohort

Article References: Abdo, B., Strack, D., Schäuffele, M., Tüngler, T. L., Imirzalioglu, C., Windhorst, A., Fritzenwanker, M., Heiss, C., & Rupp, M. (2026). Sonication versus peri-implant tissue culture in fracture-related infection: diagnostic performance and therapeutic consequences in a single-center cohort. Journal of Bone and Joint Infection, 11(4), 555-563. https://doi.org/10.5194/jbji-11-555-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-555-2026

Keywords: fracture-related infection, sonication, biofilm, peri-implant tissue culture, osteosynthesis, diagnostic sensitivity, antibiotic therapy, orthopedic surgery, implant infection, microbiology, trauma surgery, pathogen detection

The clinical challenge that motivates this work is well known to veterinary practitioners. Dogs infected with D. immitis typically show no overt clinical signs in the early stages of infection, a period during which adult worms are maturing in the pulmonary arteries and heart. By the time coughing, exercise intolerance, or weight loss appear, disease progression may already be advanced, and the prognosis can be poor. Because treatment of established heartworm infection is costly, prolonged, and carries its own risks, early detection through routine screening is a cornerstone of veterinary preventive medicine. Annual antigen testing is widely recommended, which places point-of-care tests at the center of everyday clinical practice.

The biology underlying the diagnostic approach is worth unpacking. Adult female D. immitis worms release specific glycoprotein antigens into the host’s bloodstream, primarily into the reproductive tract of the parasite and subsequently into circulating blood. Antigen tests detect these molecules rather than antibodies, which means a positive result indicates the presence of actively reproducing adult female worms rather than mere prior exposure. This is the principle shared by the three assays compared in the study: the trūRapid™ FOUR test manufactured by Antech Diagnostics, the SNAP® 4DX® Plus test from IDEXX, and the DiroCHEK® assay from Zoetis, which served as the reference standard.

To assess how well the new test performs, the researchers evaluated a total of 350 canine remnant serum samples. Each sample was run through all three assays according to the manufacturers’ instructions, allowing direct head-to-head comparison. Using DiroCHEK®, a microtiter plate ELISA widely regarded as a reference laboratory method, the panel included 149 samples that tested positive for D. immitis antigen and 201 samples that tested negative. This design allowed the team to calculate both sensitivity, the ability to correctly identify infected dogs, and specificity, the ability to correctly identify uninfected ones, with meaningful statistical confidence.

The results were striking. For the 149 DiroCHEK®-positive samples, the trūRapid™ FOUR test demonstrated a sensitivity of 98.7 percent, with a 95 percent confidence interval spanning 94.3 to 99.6 percent. In practical terms, the test missed only a small fraction of antigen-positive samples, and the upper bound of the confidence interval approached perfection. Among the 201 samples that were negative on the reference assay, the trūRapid™ FOUR test achieved a specificity of 100 percent, with a 95 percent confidence interval of 98.2 to 100 percent, meaning it produced no false positives in this sample set. For a screening test intended for annual use in apparently healthy dogs, that combination of high sensitivity and perfect observed specificity is exactly the profile clinicians hope to see.

Agreement with an established point-of-care competitor was equally strong. When trūRapid™ FOUR results were compared directly with those of the SNAP® 4DX® Plus, the two tests showed almost perfect concordance, with an agreement coefficient of 0.994 and a 95 percent confidence interval of 0.983 to 1.000. Values this close to 1.0 indicate that, across the entire sample panel, the two point-of-care assays essentially never disagreed in a way that would change a clinical decision. For veterinarians, this means switching to or adding the new test is unlikely to alter diagnostic outcomes relative to the platforms already in widespread use.

Speed and workflow matter as much as raw accuracy in the exam room. The trūRapid™ FOUR test delivers a result in approximately ten minutes, which allows a veterinarian to test a dog during a single appointment and act on the result immediately, whether that means counseling an owner about treatment or confirming that a prevention plan is working. The study’s authors conclude that the test provides reliable diagnostic accuracy, ease of use, and a fast time to result, making it a robust point-of-care option for detecting canine heartworm infection. They note that its performance is comparable both to the reference laboratory ELISA, DiroCHEK®, and to the commercially available SNAP® 4DX® Plus.

The implications extend beyond a single product evaluation. Point-of-care diagnostics have transformed veterinary medicine by moving testing out of centralized laboratories and into clinics, shelters, and field settings. In regions where heartworm is endemic, including much of the southeastern United States and expanding areas of Europe, Asia, and South America, the ability to screen reliably without shipping samples or waiting days can increase testing rates and catch infections earlier. Shelter medicine and rescue transport programs, in particular, depend on rapid, accurate screening to make sound decisions about animal movement and treatment. A validated ten-minute assay that matches laboratory performance strengthens that infrastructure.

As with any diagnostic study, context matters. The evaluation was conducted on remnant serum samples rather than whole blood drawn in a clinic, and the sample panel was defined by the reference test’s own results, so sensitivity and specificity are measured relative to DiroCHEK® rather than to an independent gold standard such as necropsy confirmation. The research was funded by Antech Diagnostics and Mars Petcare Science & Diagnostics, and the authors declared no competing interests; readers should weigh the funding source when interpreting the uniformly favorable results, even though the comparison against an independent manufacturer’s test provides a useful external benchmark. Confidence intervals, which the authors report transparently, also remind us that a 100 percent observed specificity in 201 samples still carries a small margin of statistical uncertainty.

Nevertheless, the study adds a credible new option to the veterinary diagnostic toolkit at a time when heartworm’s geographic footprint continues to shift with climate and animal movement. The findings support the use of the trūRapid™ FOUR heartworm antigen test as a dependable clinical tool for the detection and management of heartworm infection in dogs, and they underscore a broader trend: rapid immunoassays are closing the gap with laboratory reference methods. For the millions of dog owners whose pets receive annual heartworm screening, the practical takeaway is simple. The test that runs in the exam room while you wait is now backed by evidence that it performs on par with the reference laboratory, and earlier, more accessible detection remains the best defense against a disease that is far easier to prevent than to cure.

Subject of Research: Evaluation of a rapid point-of-care antigen test for detecting Dirofilaria immitis heartworm infection in dogs

Article Title: Evaluation of the trūRapid™ FOUR heartworm antigen test: a reliable point-of-care diagnostic tool for heartworm detection in dogs

Article References: Evaluation of the trūRapid™ FOUR heartworm antigen test: a reliable point-of-care diagnostic tool for heartworm detection in dogs. (n.d.). https://doi.org/10.1186/s13071-026-07630-8

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07630-8

Keywords: Dirofilaria immitis, heartworm disease, canine diagnostics, point-of-care testing, lateral flow immunoassay, antigen test, trūRapid FOUR, DiroCHEK, SNAP 4DX Plus, veterinary parasitology, diagnostic sensitivity, Parasites & Vectors

The standard workhorse for investigating a suspected stricture is endoscopic retrograde cholangiopancreatography, or ERCP, in which an endoscope is guided to the papilla of Vater and contrast is injected to outline the ducts on X-ray imaging. During the same procedure, clinicians can sample the narrowed segment in two ways. Brush cytology drags a bristled catheter across the lesion and collects shed cells for smear examination, a simple and quick technique with a low complication risk but a disappointingly modest sensitivity, historically around forty-five percent. Transpapillary forceps biopsy, by contrast, physically pinches off tissue from the stricture, yielding true histological architecture rather than isolated cells. In principle this should be more informative, but in practice it is technically demanding, requires considerable operator experience, and has long suffered from a lack of purpose-built instruments, which has kept its success rate relatively low.

The Beijing group, led by Jingxian Wei and Jiangtao Chu with senior author Shun He, set out to close that instrument gap. Their new device is a guidewire-introduced bile duct biopsy forceps with two deliberate design modifications. First, a plastic sheath tube runs alongside the forceps so that the guidewire, already positioned across the stricture, can steer the instrument through the papilla; the sheath keeps the forceps and wire sliding smoothly against each other, solving the chronic problem of guidewire displacement when forceps are repeatedly advanced and withdrawn. Second, the head of the forceps is pre-bent, which helps the jaws angle into the duct rather than scraping perpendicular to its wall. The lengthened guiding sheath and altered jaw angle together raise the technical success rate of biopsy above ninety-five percent in the developers’ design goals, and the device also permits simultaneous collection of bile for cytological examination.

To evaluate the device, the researchers conducted a single-center retrospective study of 262 patients who underwent ERCP for biliary stricture between September 2015 and August 2017. The cohort comprised 157 men and 105 women with an average age of sixty-one years. The final diagnoses were sobering in their distribution: 118 cholangiocarcinomas, 61 pancreatic cancers, 27 ampullary cancers, 16 gallbladder cancers, 23 other cancers, and 17 benign strictures, adding up to 243 malignant and 19 benign narrowings. During each procedure, after fluoroscopic evaluation of the stricture, the guidewire was kept in place across the lesion and the new forceps were advanced over it to attempt a biopsy. When feasible, a cytology brush was then passed as well. All specimens went for pathological and cytological analysis, and the final diagnosis was anchored to histocytological findings plus at least twelve months of clinical follow-up.

The headline numbers tell a clear story about combination testing. Biopsy with the new forceps succeeded in 187 of 262 cases, a technical success rate of 71.4 percent, and achieved a sensitivity for malignancy of 60.8 percent with a diagnostic accuracy of 63.1 percent. Brush cytology was performed in 247 cases, or 94.3 percent of the cohort, and reached a sensitivity of 66.1 percent and an accuracy of 67.6 percent; the brush-based pathology component using cell block technology showed 49.7 percent sensitivity, while exfoliative cytology smears from the same specimens reached 55.7 percent. Crucially, the 176 patients who received both biopsy and brush cytology, 67.2 percent of the cohort, achieved a combined sensitivity of 77.7 percent and an accuracy of 79 percent. Formal pairwise statistical comparison confirmed that the combined approach was significantly better than either method alone, with p-values of 0.012 against brushing and 0.001 against biopsy, while brushing and biopsy alone did not differ significantly from each other. Specificity was a perfect 100 percent for every method, with zero false positives.

Just as striking was the safety profile. The researchers recorded no bleeding, no perforation, no cholangitis, and no post-procedure pancreatitis, and no serious adverse events of any kind. The authors attribute this to the instrument’s design philosophy. Because the forceps slide over a guidewire that has already crossed the papilla, no sphincterotomy is needed, avoiding the cutting of the sphincter muscle that conventional forceps intubation often requires and that raises bleeding risk. Once inside the duct, the wire keeps the forceps aligned within the lumen and steers them toward the narrowed segment, preventing the perpendicular approach to the duct wall that can cause perforation. For patients with obstructive jaundice, endoscopic biliary drainage was performed afterward as routine care, and vital signs were monitored throughout under anesthesia.

The design also dovetails with a broader trend in biliary diagnostics: optimizing specimen collection rather than adding new technology. The authors point to a 2025 multicenter trial by So and colleagues showing that simply flushing residual cells from the brush sheath raised brush cytology sensitivity from 59.2 to 69.9 percent without any change in instruments or procedural steps. The new forceps’ integrated bile collection channel follows the same logic, capturing additional shed cells non-invasively within the conventional workflow, and its 66.1 percent brush sensitivity sits comfortably within the range produced by such specimen-optimization pathways. The message is that incremental refinements in how cells and tissue are harvested can rival the gains expected from expensive new imaging platforms.

The device is not a panacea, and the authors are candid about its limits. The 71.4 percent technical success rate means that in 28.6 percent of cases the forceps could not complete a biopsy, owing to instrument design constraints that sometimes require endoscopic adjustments such as repositioning the forceps flap, or to patient anatomy such as brittle tissue or a narrow opening angle of the jaws. Failure did not correlate closely with the location or severity of the stricture. Beyond the instrument, transpapillary biopsy remains blind under fluoroscopy, cannot reach purely exogenous lesions that compress the duct from outside, and struggles with the fibrous architecture of cholangiocarcinoma and the low cellularity and hardness of pancreatic cancer. Cholangioscopy-guided biopsy offers visual targeting but is costly, uncommon as a routine single-operator technique, and restricted to smaller forceps with lower tissue yield through its working channel.

The study’s own design carries caveats that the authors acknowledge. It was retrospective, single-center, and modest in size, which limits generalizability; the three sampling methods were compared across independent population samples rather than in a paired design in which every patient undergoes all three tests, which would better control for individual heterogeneity; there was no direct head-to-head comparison with conventional biopsy forceps, sheath-based systems, or cholangioscopy; and operator dependence cannot be excluded. The team is now planning a prospective randomized controlled trial to address these gaps and convert the retrospective validation into firmer evidence.

Even with those qualifications, the clinical implications are immediate. Current guidelines for pancreaticobiliary tumors insist on histological or cytological confirmation before treatment, and in centers without access to endoscopic ultrasound, ERCP-based sampling is often the only route to that confirmation. A device that lowers the technical barrier to forceps biopsy, keeps the guidewire stable, avoids sphincterotomy, and pushes combined sensitivity to nearly eighty percent offers a practical upgrade for the many hospitals where cholangioscopy is unavailable. For the roughly seventy percent of patients whose strictures prove malignant, earlier and more reliable tissue diagnosis can mean the difference between resectable and incurable disease; for the quarter whose lesions are benign, it can spare them a major operation they never needed. A modestly redesigned pair of forceps, in other words, may shift one of gastroenterology’s hardest diagnostic calls measurably in the patient’s favor.

Subject of Research: Development and clinical evaluation of guidewire-introduced bile duct biopsy forceps for diagnosing biliary strictures during ERCP

Article Title: Clinical application of a new type of guidewire-introduced bile duct biopsy forceps

Article References: Wei, J., Chu, J., Liu, P., Wang, J., Ke, Y., Liu, X., Zhang, Y., Dou, L., Liu, Y., Liang, R., & He, S. (2026). Clinical application of a new type of guidewire-introduced bile duct biopsy forceps. Holistic Integrative Oncology, 5(1), Article 44. https://doi.org/10.1007/s44178-026-00260-1

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00260-1

Keywords: ERCP, biliary stricture, bile duct biopsy, brush cytology, cholangiocarcinoma, malignant biliary stricture, transpapillary forceps biopsy, guidewire, endoscopy, diagnostic sensitivity, pancreaticobiliary tumors, medical devices

The underlying biology is straightforward but consequential. Bilirubin is the yellow pigment produced when the heme portion of hemoglobin is catabolized, and every molecule of bilirubin generated corresponds to one molecule of carbon monoxide released as heme oxygenase does its work. In newborns, whose livers are still maturing and whose red cell lifespan is shorter than in older children and adults, any acceleration of red cell destruction can push bilirubin concentrations upward rapidly. When bilirubin crosses the blood-brain barrier in sufficient quantities, it can cause acute bilirubin encephalopathy and permanent kernicterus, a devastating outcome that modern screening and phototherapy are designed to prevent. Identifying hemolysis early therefore gives clinicians a chance to intervene before bilirubin levels reach neurotoxic territory.

The study at the center of the dispute, conducted by Burch and colleagues, compared the direct antiglobulin test, commonly known as the DAT or Coombs test, against end-tidal carbon monoxide corrected for ambient carbon monoxide, abbreviated ETCOc, across three threshold levels. The DAT has long been the traditional tool for flagging immune-mediated hemolysis, particularly in infants whose mothers have antibodies that cross the placenta and coat the fetal red cells. It detects antibody bound to the infant’s red blood cells, which is an indirect and imperfect proxy for whether red cells are actually being destroyed at an accelerated rate. Many infants with clinically significant hemolysis test negative, and many DAT-positive infants never develop problematic bilirubin elevations.

The performance numbers cited in the correspondence are striking. Schutzman endorses the Burch group’s finding that the DAT had a sensitivity of only 13 percent for identifying hemolysis as a neurotoxicity risk factor, meaning the vast majority of hemolyzing infants went undetected by the blood test. ETCOc, by contrast, achieved a sensitivity of 88 percent at a correction threshold of 2.1 parts per million. The logic of the breath test follows directly from heme catabolism: because carbon monoxide is exhaled in proportion to bilirubin production, measuring it in the terminal portion of the infant’s exhaled breath, after subtracting background carbon monoxide in the ambient air, provides a direct physiological readout of the rate of red cell destruction. The approach has been refined over decades, and nomograms establishing reference ranges for term and late-preterm infants, including work in Chinese newborn populations, have helped define what constitutes abnormal heme catabolism in the first days of life.

Where Schutzman parts company with the original study is in its conclusion that ETCOc screening would lead to overdiagnosis, overtreatment, and higher costs. He argues that this conclusion rests on prevalence-dependent quantities, specifically the rates of indicated testing and phototherapy observed in the study cohort, and that those rates cannot be generalized to routine screening. Although all nursery admissions were nominally eligible for the Burch study, the authors themselves acknowledged that their cohort was enriched with DAT-positive and hyperbilirubinemic infants. In other words, the sample was not representative of an ordinary well-baby nursery population, and any cost or treatment projections drawn from it inherit that bias.

The magnitude of the bias, as Schutzman lays it out, is considerable. The Burch cohort showed a phototherapy rate of 9 percent, which he notes is more than fourfold the 2.1 percent rate reported in the same eight-hospital network when an unselected population of 22,455 infants was examined in earlier work by Sarathy and colleagues. That earlier study, published in Pediatrics, examined bilirubin measurement and phototherapy use after the American Academy of Pediatrics issued its 2022 newborn hyperbilirubinemia guideline, providing a large benchmark for what phototherapy utilization actually looks like across a broad, unselected nursery population. A selective sample, Schutzman contends, simply cannot support conclusions about what would happen if ETCOc were adopted for routine or universal screening.

To make the counterpoint concrete, the correspondence points to the only study to date that evaluated a large, continuous cohort of all admissions to a well-baby nursery. That investigation, by Wells and colleagues and published in the Journal of Perinatology in 2025, examined end-tidal carbon monoxide monitoring for significant hemolysis in the routine management of newborn hyperbilirubinemia. Its findings ran in the opposite direction from the overdiagnosis concern: when ETCOc was used across an unselected population, it was associated with reductions in serum bilirubin sampling, in phototherapy use, and in readmissions. The mechanistic explanation is plausible. If a breath test reliably identifies which infants are truly hemolyzing, clinicians can reserve blood draws and treatment for those who need them, while confidently observing infants whose bilirubin production is normal, rather than reflexively testing and treating based on an insensitive proxy.

The correspondence also situates the debate within a broader effort to establish a definitive reference standard for neonatal hemolysis. A 2023 review by Christensen, Stevenson, Bhutani, and coauthors asked whether any test could serve as a gold standard for diagnosing and quantifying hemolysis in neonates and infants, highlighting the inherent difficulty of the problem. Hemolysis is a dynamic process, its rate changing hour by hour in the first days of life, and no single static measurement captures it perfectly. Earlier collaborative work by Bhutani, Maisels, Schutzman, and colleagues published in Acta Paediatrica in 2018 addressed the identification of risk for neonatal hemolysis directly, helping to frame ETCOc as a physiologically grounded candidate for that role. The current exchange is thus not an isolated squabble over a single study but part of a decade-long effort to replace indirect markers with a direct measure of heme catabolism.

What hangs on this methodological dispute is far from academic. Severe neonatal hyperbilirubinemia remains one of the most common reasons for newborn readmission, and kernicterus, while rare in well-resourced settings, is entirely preventable when at-risk infants are recognized in time. A screening strategy that misses nearly nine out of ten hemolyzing infants, as a 13 percent sensitivity implies, leaves a substantial reservoir of risk undetected, particularly among infants whose hemolysis is not immune-mediated and would never be flagged by a DAT. Conversely, an approach that indiscriminately expands testing and treatment burdens families and health systems. The correspondence argues that the evidence points toward the breath test as the more faithful instrument, and that fears of overtreatment rest on a biased sample rather than on data from the populations in which routine screening would actually be deployed.

For now, the field awaits the kind of large, unselected, prospective studies that both sides agree would settle the question. The correspondence itself declares no funding, and its author discloses only an unpaid advisory role with a company in the field, Capnia, Inc., alongside affiliations with Jefferson Einstein Philadelphia Hospital, Thomas Jefferson University Hospital, and Nemours Children’s Hospital Delaware. Whether ETCOc moves from research tool to standard nursery practice will depend on whether the reductions in blood sampling, phototherapy, and readmissions seen in the Wells cohort can be replicated at scale. But the core physiological insight at the heart of the debate, that every bilirubin molecule announces itself in a puff of exhaled carbon monoxide, continues to make the breath test a compelling candidate for catching the hemolyzing newborn before jaundice becomes dangerous.

Subject of Research: Comparison of the direct antiglobulin test and end-tidal carbon monoxide measurement for detecting hemolytic hyperbilirubinemia in newborns

Article Title: Hemolytic hyperbilirubinemia

Article References: Schutzman, D. L. (2026). Hemolytic hyperbilirubinemia. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02919-z

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02919-z

Keywords: neonatal jaundice, hyperbilirubinemia, hemolysis, end-tidal carbon monoxide, direct antiglobulin test, phototherapy, newborn screening, bilirubin, kernicterus, neonatology, Journal of Perinatology, diagnostic sensitivity

The research team, led by Michelle Larsen and including McKenna Willis, Valeria Scorza, Sangeeta Rao, and Michael Lappin from the Department of Clinical Sciences and the Center for Companion Animal Studies at Colorado State University, set out with a clear primary objective: to compare Giardia cyst detection results among several traditional fecal flotation techniques and an AI-enabled cyst assay, using fecal samples from shelter dogs with diarrhea. The traditional methods included zinc sulfate centrifugation with expert read, sugar centrifugation with expert read, and direct fluorescent antibody testing, known as DFA, also with expert read. The AI platform under evaluation was the Vetscan Imagyst system manufactured by Zoetis, which is designed for in-clinic use and can detect Giardia cysts in approximately ten minutes using machine-learning algorithms trained to recognize the distinctive morphology of the cysts in digitized images of fecal preparations.

The choice of comparator methods reflects the practical realities of veterinary diagnostics. Centrifugal fecal flotation remains the workhorse of most small animal clinics because it is inexpensive and requires only basic equipment, but its performance varies with the flotation solution used. Zinc sulfate centrifugation is widely regarded as one of the better flotation methods for recovering Giardia cysts, while sugar centrifugation is commonly used for the broader detection of gastrointestinal parasites. DFA, by contrast, uses fluorescently labeled antibodies that bind specifically to Giardia cysts, making it one of the most sensitive detection methods available, but it demands specialized fluorescence microscopy and trained personnel, which places it beyond the reach of most general practices. By anchoring the comparison to DFA and to expert-read flotation, the investigators created a benchmark that any point-of-care technology would have to approach closely to be considered clinically credible.

The study’s headline numbers are instructive. When DFA served as the reference standard, the AI-enabled Giardia cyst assay achieved a sensitivity of 71.4 percent and a specificity of 94.8 percent. Zinc sulfate centrifugation with expert read, measured against the same DFA benchmark, posted an identical sensitivity of 71.4 percent but a perfect specificity of 100 percent. When the two non-DFA methods were compared directly with each other, zinc sulfate centrifugation with expert read versus the AI-enabled cyst assay, the AI system delivered 80.0 percent sensitivity and 89.4 percent specificity. In other words, the machine-driven assay performed in roughly the same diagnostic territory as the expert-performed flotation technique that most clinics already rely on, and neither matched the analytic sensitivity of DFA, which detects cysts that both other methods can miss.

One of the most technically interesting parts of the study involved the use of polymerase chain reaction, or PCR, to adjudicate the discordant results. There were three samples that tested positive by DFA but negative by the AI-enabled Giardia cyst assay, and PCR confirmed that all three of these were genuinely false negatives on the AI side. Conversely, there were three samples that were negative by DFA but positive by the AI-enabled assay, and PCR confirmed that two of these were actually false negatives by DFA, meaning the AI system had correctly flagged infections that the antibody-based reference method had missed. This kind of molecular tie-breaking is a valuable feature of modern diagnostic studies, because it reveals that no single method is infallible and that apparent errors on one platform may in fact reflect limitations of the comparator rather than of the technology being tested.

The investigators also evaluated an AI-enabled fecal ova and oocyst assay, a broader screening mode intended to detect a range of gastrointestinal parasites rather than Giardia specifically, as a Giardia detection tool. This assay produced the lowest sensitivity for Giardia cysts among the methods tested, and the team concluded that it should not be used for Giardia detection, reserving that role for the dedicated Giardia cyst assay mode. The distinction matters operationally: the same imaging platform can run different algorithmic modes optimized for different targets, and the study demonstrates that performance characteristics do not necessarily transfer between modes. A general parasite screen that performs well for hookworm eggs or roundworm ova may not be tuned finely enough to catch Giardia cysts, which are smaller and morphologically subtler than many helminth eggs.

A secondary objective of the study used the same sample set to verify earlier published findings on other common gastrointestinal parasites, comparing AI-enabled parasite detection with sugar centrifugation read by experts. The results for detecting these other parasites, which include hookworms of the genus Ancylostoma, roundworms of the genus Toxocara, the whipworm Trichuris vulpis, and coccidian parasites of the genus Cystoisospora, were similar to those reported in prior studies. This replication is significant because it suggests that the earlier positive evaluations of AI-assisted fecal screening were not artifacts of a particular sample population or laboratory environment, but reflect a reproducible level of performance across different cohorts of diarrheic dogs.

From a veterinary practice standpoint, the implications are straightforward. Most small animal clinics do not employ a parasitology expert, and few have the fluorescence equipment needed to run DFA in house. Samples that require those capabilities are typically shipped to reference laboratories, adding days of delay during which an infected dog may continue to shed cysts into the environment and potentially infect other animals or, in the case of zoonotic concerns around Giardia, pose questions for the household. An AI-enabled system that returns a Giardia result in roughly ten minutes, with agreement comparable to expert centrifugal flotation, offers a way to move accurate parasitological diagnosis into the exam room, enabling same-visit treatment decisions and faster infection control in shelters, boarding facilities, and multi-dog households.

The authors conclude that the overall results from the three principal methods were similar, and they suggest that the AI-enabled Giardia cyst assay could be considered for use in small animal clinics for Giardia and other parasite detection, particularly in settings where a parasite expert or DFA testing is not routinely available. That framing is appropriately measured. The study does not claim that the AI system outperforms expert microscopy or DFA; rather, it demonstrates that the technology achieves clinically acceptable agreement with established methods while removing the dependence on scarce human expertise. For clinics that already have access to skilled microscopists and reference laboratory support, the traditional methods remain fully viable, and DFA retains its place as the most sensitive option when the clinical stakes demand maximal detection.

The study also illustrates the evolving relationship between commercial diagnostic developers and academic veterinary research. Zoetis provided the AI-enabled device and its supplies for the study, and the corresponding author, Michelle Larsen, is currently a full-time employee of Zoetis while completing a master’s program at Colorado State University; the company supplied the instruments but, according to the published declarations, did not influence study design, data analysis, or other portions of the research. Transparency about such arrangements is essential as AI diagnostics proliferate, and the open-access publication allows independent readers to scrutinize the sensitivity and specificity figures for themselves. As machine-learning diagnostic platforms continue to spread through veterinary medicine, studies of this kind, which benchmark them rigorously against expert-read traditional methods and use PCR to resolve discordant results, will be the standard against which their clinical adoption is judged.

Subject of Research: Comparison of AI-enabled and traditional diagnostic methods for detecting Giardia and other enteric parasites in diarrheic dogs

Article Title: Comparison of traditional and artificial intelligence methods for detection of enteric pathogens in feces of dogs with diarrhea

Article References: Larsen, M., Willis, M., Scorza, V., Rao, S., & Lappin, M. (2026). Comparison of traditional and artificial intelligence methods for detection of enteric pathogens in feces of dogs with diarrhea. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07685-7

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07685-7

Keywords: Giardia duodenalis, artificial intelligence, veterinary diagnostics, fecal flotation, direct fluorescent antibody, PCR, dogs, point-of-care testing, intestinal parasites, Parasites & Vectors, Colorado State University, diagnostic sensitivity

The assay at the heart of the study targets methylation changes in five genes: SEPTIN9, BCAT1, IKZF1, BCAN and VAV3. DNA methylation is an epigenetic modification in which methyl groups are added to cytosine bases, typically at CpG dinucleotides, altering gene expression without changing the underlying genetic code. Cancer cells acquire highly characteristic methylation patterns, including widespread silencing of tumor-suppressor genes through promoter hypermethylation. Because these patterns are stable, reproducible and often tissue- or tumor-specific, methylated DNA fragments released into the bloodstream by dying tumor cells serve as a molecular fingerprint of malignancy. Circulating cell-free DNA, or cfDNA, carries these marks, and polymerase chain reaction-based assays can be designed to detect them even when tumor-derived fragments represent only a tiny fraction of the total cfDNA pool, which is otherwise dominated by DNA from blood cells.

SEPTIN9 is the most familiar name on the list, having already underpinned a commercially available plasma test for colorectal cancer screening in several countries. BCAT1, IKZF1, BCAN and VAV3 add complementary signals, and the logic of a multi-gene panel is straightforward: no single methylation marker is shed by every tumor, so combining several independent targets increases the chance that at least one will be detectable in a given patient. The five-gene assay evaluated here converts methylation measurements across these targets into a single composite result, classified as positive or negative, which was then benchmarked against pathology, the gold standard that definitively establishes whether a patient has cancer after tissue examination.

The study population came from a single colorectal surgery department, a design choice with important implications for how the results should be read. All 412 patients had plasma cfDNA methylation testing and routine serum tumor-marker evaluation performed either before surgery or before starting treatment, and each case was adjudicated by pathology. The final analysis compared 219 patients with confirmed colorectal cancer against 193 patients whose diagnoses were not colorectal cancer, a mix that reflects the genuine clinical question a hospital faces: distinguishing malignant from non-malignant disease among symptomatic patients referred to a surgical service. This is a harder and more realistic test than comparing cancer patients against healthy volunteers, because the control group includes people with polyps, inflammatory conditions and other colorectal pathologies that can confound biomarker performance.

The headline numbers tell a consistent story. The methylation assay achieved a sensitivity of 73.5 percent, meaning it correctly flagged roughly three out of four cancers, with a 95 percent confidence interval running from 67.7 to 79.4 percent. Its specificity of 91.2 percent, with a confidence interval of 87.2 to 95.2 percent, indicates that false positives were relatively uncommon. The area under the receiver operating characteristic curve, a summary of overall discriminatory ability that ranges from 0.5 for a useless test to 1.0 for a perfect one, reached 0.873. CEA, by contrast, detected only 35.9 percent of cancers, though its specificity was higher at 96.7 percent, yielding an AUC of 0.730. The difference in AUC between the two tests was statistically significant, with a p-value below 0.001 on the DeLong test, a standard method for comparing correlated receiver operating characteristic curves.

The researchers also explored whether combining the two markers would help. An either-positive rule, in which a patient is considered positive if either the methylation assay or CEA is positive, pushed sensitivity up to 79.9 percent but dragged specificity down to 88.6 percent, producing an AUC of 0.843. That trade-off illustrates a fundamental principle of diagnostic test design: combining tests with independent signals raises the chance of catching true cases but simultaneously accumulates false positives from each component. For a test intended as an adjunctive risk-stratification tool rather than a standalone diagnosis, the modest gain in sensitivity may or may not justify the additional false positives, a calculation that depends on the clinical setting, the cost of follow-up colonoscopy and the prevalence of disease in the tested population.

Perhaps the most biologically revealing results concern how performance scaled with tumor burden. Sensitivity climbed from 56.8 percent in stage I disease to 100 percent in stage IV, from 38.1 percent in T1 tumors to 94.1 percent in T4 tumors, and from 53.6 percent in tumors measuring two centimeters or less to 95.0 percent in tumors larger than six centimeters. This gradient is exactly what the biology of circulating tumor DNA predicts. Early tumors are small, have limited cell turnover and relatively poor blood supply at their margins, so they shed comparatively little DNA into circulation. Advanced tumors, with larger mass, greater necrosis and more active remodeling of the tumor microenvironment, release far more methylated DNA fragments, making them easier to detect. The pattern is a double-edged sword: it confirms the assay is genuinely measuring tumor-derived material, but it also means the test is weakest precisely where a screening tool would deliver the greatest benefit, at the earliest and most curable stages.

This stage dependence is not a flaw unique to this assay; it is an inherent constraint of liquid biopsy technology that the field has grappled with since its inception. Detecting a handful of tumor DNA fragments among the vast background of healthy cfDNA is an analytical challenge comparable to finding a needle in a haystack, and the needle count rises with tumor size and stage. Strategies to improve early detection include deeper sequencing, larger panels of methylation targets, optimized DNA extraction and amplification chemistry, and multimodal algorithms that integrate methylation with other features such as fragmentomics and mutation profiling. The authors of the current study are careful to frame their five-gene assay as a complement to existing modalities, including colonoscopy and established screening programs, rather than a replacement for them.

The real-world design of the study is both its greatest strength and its principal limitation. By testing the assay in a consecutive clinical cohort from a single surgical department, the researchers captured performance under the messier conditions of actual practice, where patient characteristics, sample handling and comorbidities deviate from the idealized settings of model-development studies. Yet the single-center, single-department, retrospective nature of the work means the findings cannot be generalized wholesale. A cohort drawn from a colorectal surgery clinic overrepresents symptomatic patients and advanced disease, so sensitivity in an asymptomatic screening population would likely be lower than the figures reported here. Specificity, too, depends on the composition of the control group, and a healthier population might shift the numbers in either direction. The authors themselves emphasize that large-scale, multi-center prospective studies are needed to define the assay’s utility across diverse screening and diagnostic settings before it can be recommended for broad clinical deployment.

Even with those caveats, the study adds meaningful weight to the case for methylation-based liquid biopsy in colorectal cancer, a disease that remains one of the most common and deadly malignancies worldwide despite being highly curable when caught early. A blood test that reliably outperforms CEA, a marker that has been in clinical use for decades yet misses nearly two-thirds of cancers in this cohort, represents a tangible step toward less invasive and more accessible detection pathways. The five-gene panel’s 0.873 AUC in a real-world surgical cohort, achieved with a technically simple PCR-based workflow on routine plasma samples, suggests that epigenetic blood testing is maturing from promising concept to clinically credible instrument. The road ahead runs through prospective validation in screening populations, standardization of laboratory protocols and careful health-economic analysis, but the direction of travel is now unmistakable: the chemical marks that tumors stamp on their DNA are becoming a readable, quantifiable and increasingly trustworthy signal in modern cancer medicine.

Subject of Research: Diagnostic performance of a five-gene plasma cell-free DNA methylation assay for colorectal cancer detection compared with CEA

Article Title: Performance of a five-gene plasma cfDNA methylation assay for colorectal cancer detection: a single-center real-world analysis

Article References: Chen, B., Xu, X., Yuan, H., Wan, Z., Du, W., Yu, Q., Qian, Y., Wang, J., Yu, Y., Lyu, J., Yang, Z., & Zheng, B. (2026). Performance of a five-gene plasma cfDNA methylation assay for colorectal cancer detection: a single-center real-world analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17047-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17047-2

Keywords: colorectal cancer, cfDNA methylation, liquid biopsy, SEPTIN9, CEA, early detection, epigenetics, tumor biomarkers, real-world study, BMC Cancer, diagnostic sensitivity, circulating tumor DNA